Last updated: February 15, 2026
NDC 84386-0034 corresponds to Zolpimist (zolpidem oral spray), a prescription sleep aid used primarily for short-term management of insomnia. Its market landscape involves regulatory approval, competitive positioning, and pricing strategies within the sleep aid segment.
Market Overview
-
Indication and Usage: Designed for patients requiring rapid onset sleep treatment, especially those with difficulty swallowing pills.
-
Regulatory Status: Approved by the FDA, with labeling indicating use for short-term insomnia.
-
Market Size: Estimated US insomnia treatment market surpasses $3 billion annually. Zolpidem-based products constitute a significant share, with immediate-release formulations being dominant.
-
Competitive Landscape:
- Traditional Oral Tablets (Ambien, Ambien CR)
- Other Fast-Acting Schedule IV Sleep Aids (Lunesta, Sonata)
- Alternative Delivery systems (melatonin sprays, OTC products)
-
Market Penetration: Zolpimist accounts for a niche segment, mainly among patients preferring spray administration or with swallowing difficulties.
Regulatory and Reimbursement Environment
- FDA Labeling: Emphasizes short-term use, potential for dependence.
- Pricing and Reimbursement: Reimbursed through private insurers, Medicare Part D plans. Brand name pricing tends to be high, with generic availability influencing price dynamics.
Pricing Analysis
Projection Models
| Year |
Estimated Market Size (USD millions) |
Price per Unit (USD) |
Sales Volume (Units in millions) |
Total Revenue (USD millions) |
| 2023 |
150 |
250 |
0.6 |
150 |
| 2024 |
180 |
250 |
0.72 |
180 |
| 2025 |
200 |
220 (discounted) |
0.9 |
198 |
| 2026 |
220 |
200 (generic availability) |
1.1 |
220 |
Assumptions: Market share stabilizes; price reductions occur as generics gain market share; overall demand upticks due to increased sleep disorder diagnosis.
Key Market Drivers & Risks
-
Drivers:
- Increasing prevalence of insomnia, especially among aging populations.
- Growing preference for alternative delivery methods.
- Patent expiry and generic entry, lowering prices.
-
Risks:
- Regulatory constraints or safety warnings limiting use.
- Competition intensifies with emerging generic products.
- Insurance coverage thresholds influencing patient access and price sensitivity.
Conclusion
The market for NDC 84386-0034, Zolpimist, remains niche but stable within the broader sleep aid sector. Its current price point aligns with premium delivery methods, though volume pressures and generics are poised toshape the next five years. Price projections suggest a decline from approximately $250 to $200 per unit over the next three years, driven by generic competition and evolving prescribing habits.
Key Takeaways
- Zolpimist commands a premium pricing due to unique spray delivery, with a current AWIP (Average Wholesale Price) around $250.
- Market growth remains tied to insomnia prevalence, but price pressures from generics may reduce unit costs.
- Product differentiation, such as ease of use for specific populations, sustains niche demand.
- Competitive landscape shifts depend heavily on regulatory changes and patent exclusivity status.
- Future projections indicate stable revenue with declining prices as generics enter the market.
FAQs
1. What is the primary clinical advantage of Zolpimist over traditional oral tablets?
It offers rapid onset and ease of swallowing, beneficial for patients who have difficulty with pill ingestion.
2. How does regulatory status influence pricing for sleep aids like Zolpimist?
Regulatory approval and labeling restrictions regarding safety or duration of use significantly impact reimbursement and market penetration.
3. What factors could accelerate generic entry for zolpidem sprays?
Patent expiration, generic API manufacturing approvals, and regulatory clearances for alternative delivery forms.
4. How do insurance reimbursement policies affect net pricing for Zolpimist?
Reimbursement levels influence patient out-of-pocket costs, impacting demand and achievable price points.
5. What are the critical elements for market share growth in the wake of generic competition?
Brand reputation, formulation differentiation, targeted marketing, and physician prescribing patterns.
Sources:
[1] IQVIA, "Pharmaceutical Market Data," 2023.
[2] FDA, "Zolpidem Formulations," 2022.
[3] Evaluated pricing trends from GoodRx and wholesale price databases, 2023.
